This site is intended for US Healthcare Professionals only.
neffyconnect logo

Support services designed for your patients

A blue icon of a medical professional holding a green first aid kit with a blue plus sign in a white heart on it
Helps patients get the neffy they need, even if insurance barriers arise
  • BlinkRx can help with formulary exceptions/prior authorizations and appeals
  • Patients can have their neffy filled by BlinkRx or a pharmacy of their choice
A blue icon of a hand holding a green dollar bill with a blue money sign on it
Helps patients afford their neffy
  • Co-Pay Savings Program:
    • Eligible, commercially insured patients may pay as little as $25 per prescription*
  • ARS Patient Assistance Program:
    • ARS Pharma provides medically necessary neffy free of charge to qualifying applicants through its Patient Assistance Program
    • Visit ARS-Pharma.com to learn more
*Terms and conditions apply.
A blue icon of two stacked screens with green and blue tools and resources on them
Dedicated support staff, allergy resources, and tools for your patients
  • Patients can connect with case managers and receive emails from neffyconnect with helpful resources and tools

Inform your patients about the comprehensive support, educational resources, and financial assistance they may be eligible to receive by signing up for neffyconnect

ACCESS neffyconnect

Demonstration devices can be a valuable tool for ensuring patient education and familiarity with how to use neffy

Bubble Blue Gradient
Bubble Blue Gradient

IMPORTANT SAFETY INFORMATION & INDICATION

+

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.